Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease

Overview of attention for article published in American Journal of Gastroenterology, August 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 1 news outlet
twitter: 35 X users
patent: 1 patent

facebook: 2 Facebook pages
wikipedia: 2 Wikipedia pages
reddit: 2 Redditors

Readers on

mendeley: 59 Mendeley

So far, Altmetric has seen 2 citations on 2 Wikipedia pages.

French

AXA1125

Cited by user Atchoum on 16 Jun 2024

AXA1125 est un médicament expérimental développé par Axcella Health qui « augmente la β-oxydation et amélioré la bioénergétique dans des modèles précliniques ».

English

AXA1125

Cited by user Buidhe on 03 Dec 2023

AXA1125 is an experimental drug developed by Axcella Health that "increased β-oxidation and improved bioenergetics in preclinical models".

This page shows the most recent Wikipedia articles that mention this research output. Click here to find out how to access more activity.